238 research outputs found
sj-pdf-1-vmj-10.1177_1358863X231155308 – Supplemental material for Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease
No full textSupplemental material, sj-pdf-1-vmj-10.1177_1358863X231155308 for Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease by Mario Enrico Canonico, Judith Hsia, Connie N Hess and Marc P Bonaca in Vascular Medicine</p
10.1177_1358863X19892690_Supplementary_tables_and_figures – Supplemental material for Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial
No full textSupplemental material, 10.1177_1358863X19892690_Supplementary_tables_and_figures for Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial by Arman Qamar, David A Morrow, Mark A Creager, Benjamin M Scirica, Jeffrey W Olin, Joshua A Beckman, Sabina A Murphy and Marc P Bonaca in Vascular Medicine</p
sj-pdf-1-vmj-10.1177_1358863X241228542 – Supplemental material for Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD
No full textSupplemental material, sj-pdf-1-vmj-10.1177_1358863X241228542 for Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD by R Kevin Rogers, Joerg Herold, Nicholas Govsyeyev, Roberto Iezzi, Justin Morrison, Shea E Hogan, Mark Nehler, Rory Bricker, Brice Andring, Brian Bergmark, Matt Cavender, Emily Malgor, Donald Jacobs, Michael N Young, Warren Capell, Joseph W Yčas, Sonia S Anand, Scott D Berkowitz, E Sebastian Debus, Lloyd P Haskell, Eva Muehlhofer, Manesh R Patel, Connie N Hess, Rupert M Bauersachs, Victoria Anderson and Marc P Bonaca in Vascular Medicine</p
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
No full text[Figure: see text
Descending Aortic Dissection, Penetrating Aortic Ulcer, and Intramural Hematoma (Acute and Chronic) Including Kommerell’s Diverticulum
No full text
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
No full textBackground: Our dual aims were as follows: (1) to classify new or recurrent myocardial infarctions (MI) in patients with stable atherosclerosis using the Universal Definition of MI classification system; and (2) to characterize the effects of vorapaxar, a first‐in‐class platelet protease‐activated receptor ‐1 antagonist, on new or recurrent MI. Methods and Results: We analyzed data from TRA 2°P‐TIMI 50, a multinational, randomized, double‐blind, placebo‐controlled trial of vorapaxar. This analysis included 20 770 patients with previous MI or peripheral arterial disease without a history of transient ischemic attack or stroke. Each new or recurrent MI after randomization that met the trial end point definition was further categorized according to the European Society of Cardiology, American College of Cardiology, American Heart Association, World Heart Federation Universal Definition classification of type and size. Of 1095 incident MIs, 77% were spontaneous (Type 1), with a smaller number (9.8%) of secondary MIs (Type 2). Vorapaxar reduced Type 1 MI (hazard ratio [HR] 0.84, CI 0.73–0.98, P=0.024), with a similar pattern for Type 2 MI (HR 0.74, CI 0.49–1.10, P=0.13). Notably, vorapaxar showed a consistent pattern of reduction across size of MIs, including MIs in the highest Universal MI size class (≥10× upper reference limit, HR 0.83, CI 0.70–0.98, P=0.025). As such, there was a significant reduction in larger, spontaneous MIs (Type 1, ≥10× upper reference limit, HR 0.81, CI 0.67–0.99, P=0.036), and a consistent pattern with respect to fatal MI (HR 0.66, CI 0.39–1.11, P=0.12). Conclusions: Among stable patients with established atherosclerosis, the most common type of incident MI is spontaneous MI, and the reduction in MI with vorapaxar was consistent across MIs of varying type and size, including spontaneous infarctions ≥10× upper reference limit. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00526474.Version of Recor
- …
